ResMed (RMD) Stock Forecast & Price Target

$237.27 +5.69 (+2.46%)

(As of 12/20/2024 05:45 PM ET)

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 13 Analyst Ratings

Sell
1

Hold
6

Buy
6

Based on 13 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 1 has given a sell rating, 6 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for RMD.

Consensus Price Target

$227.91
-3.95% Downside

According to the 13 analysts' twelve-month price targets for ResMed, the average price target is $227.91. The highest price target for RMD is $283.00, while the lowest price target for RMD is $180.00. The average price target represents a forecasted downside of -3.95% from the current price of $237.27.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

RMD Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	9 Buy rating(s)
Hold	6 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$227.91	$225.70	$199.70	$202.33
Forecasted Upside	-3.95% Downside	-7.42% Downside	-18.88% Downside	18.05% Upside
Consensus Rating	Hold	Moderate Buy	Hold	Moderate Buy

Vladimir Lenin was right… (Ad)

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Medical Companies	S&P 500
Consensus Rating Score	2.46	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-3.95% Downside	25,828.59% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent RMD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/13/2024	Stifel Nicolaus 4 of 5 stars		Initiated Coverage	Hold	$250.00	+3.09%
10/25/2024	KeyCorp 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$251.00 ➝ $266.00	+3.55%
10/25/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Sector Perform ➝ Sector Perform	$224.00 ➝ $232.00	-9.68%
10/25/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
10/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$280.00 ➝ $283.00	+18.39%
9/26/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$240.00 ➝ $270.00	+11.12%
Get the Latest News and Ratings for RMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.
9/24/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/18/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Peer Perform ➝ Underperform	$180.00	-28.25%
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Chevrier Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
3/27/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$215.00	+9.88%
1/25/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$175.00 ➝ $180.00	-3.41%
1/9/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$160.00 ➝ $195.00	+7.32%
10/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$180.00 ➝ $169.00	+21.82%
10/5/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$240.00 ➝ $165.00	+11.49%
1/31/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kaczor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 01:26 AM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, December 13, 2024. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

Strong Earnings Performance: ResMed Inc. reported earnings per share (EPS) of $2.20, exceeding the consensus estimate of $2.03 by $0.17, indicating robust financial health and effective management.
Revenue Growth: The company achieved quarterly revenue of $1.22 billion, surpassing analyst expectations of $1.19 billion, reflecting a year-over-year revenue increase of 11.1%.
Attractive Dividend: ResMed Inc. announced a quarterly dividend of $0.53 per share, translating to an annualized dividend of $2.12 and a yield of 0.87%, providing a steady income stream for investors.
Positive Analyst Ratings: Recent upgrades from brokerages, including a "buy" rating from StockNews.com and increased price targets from Bank of America and KeyCorp, suggest strong market confidence in the stock.
High Return on Equity: The company boasts a return on equity of 25.53%, indicating efficient use of shareholders' equity to generate profits, which is a positive sign for potential investors.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

Insider Selling: Recent insider sales of 68,334 shares worth over $16 million may raise concerns about the company's future prospects and insider confidence.
Moderate Buy Rating: While the stock has received upgrades, the average rating remains a "Moderate Buy," which may indicate a lack of overwhelming confidence among analysts.
Dividend Payout Ratio: The company's payout ratio stands at 28.08%, which, while sustainable, may limit the potential for future dividend increases if earnings do not grow significantly.
Market Volatility: As a medical equipment provider, ResMed Inc. may be subject to market fluctuations and regulatory changes that could impact its performance and stock price.
Competitive Landscape: The healthcare market is highly competitive, and ResMed Inc. faces challenges from other companies in the Sleep and Respiratory Care segments, which could affect its market share and profitability.

RMD Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $227.91, with a high forecast of $283.00 and a low forecast of $180.00.
: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There is currently 1 sell rating, 6 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RMD, but not buy additional shares or sell existing shares.
: According to analysts, ResMed's stock has a predicted downside of -3.95% based on their 12-month stock forecasts.
: Over the previous 90 days, ResMed's stock had 1 upgrade by analysts.
: ResMed has been rated by research analysts at Baird R W, Bank of America, KeyCorp, Needham & Company LLC, Robert W. Baird, Royal Bank of Canada, and Stifel Nicolaus in the past 90 days.
: Analysts like ResMed less than other "medical" companies. The consensus rating for ResMed is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

This page (NYSE:RMD) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Stock Forecast & Price Target